T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2B |
| 2 |
Sea Limited
SE
|
+$1.34B |
| 3 |
Morgan Stanley
MS
|
+$1.23B |
| 4 |
Incyte
INCY
|
+$1.05B |
| 5 |
Ross Stores
ROST
|
+$968M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.05B |
| 2 |
VMW
VMware, Inc
VMW
|
+$1.5B |
| 3 |
Visa
V
|
+$1.16B |
| 4 |
JPMorgan Chase
JPM
|
+$1.13B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.01% |
| 2 | Healthcare | 17.6% |
| 3 | Consumer Discretionary | 14.37% |
| 4 | Financials | 11.89% |
| 5 | Communication Services | 10.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Fox Class A
FOXA
$27.5B
| $107M | 0.01% |
3,976,898
+5,876
| +0.1% | +$159K |
|
627
Tandem Diabetes Care
TNDM
$1.61B
| $106M | 0.01% |
1,072,275
+579,116
| +117% | +$46.2M |
|
628
Hanover Insurance
THG
$7.77B
| $105M | 0.01% |
1,036,575
+55,286
| +6% | +$5.42M |
|
629
PagerDuty
PD
$932M
| $104M | 0.01% |
3,617,844
-3,353,614
| -48% | -$80.9M |
|
630
WSFS Financial
WSFS
$4.17B
| $103M | 0.01% |
3,577,818
+195,538
| +6% | +$5.18M |
|
631
Cal-Maine
CALM
$3.87B
| $103M | 0.01% |
2,306,393
-20,484
| -0.9% | -$872K |
|
|
PPD
632
DELISTED
PPD, Inc. Common Stock
PPD
| $102M | 0.01% |
3,823,385
-285,298
| -7% | -$7.13M |
|
633
Magnolia Oil & Gas
MGY
$6.13B
| $102M | 0.01% |
16,835,560
+371,054
| +2% | +$2.03M |
|
|
TCDA
634
DELISTED
Tricida, Inc. Common Stock
TCDA
| $102M | 0.01% |
3,705,162
+214,899
| +6% | +$5.85M |
|
635
US Physical Therapy
USPH
$1.24B
| $102M | 0.01% |
1,256,494
+58,426
| +5% | +$4.26M |
|
636
Towne Bank
TOWN
$3.5B
| $102M | 0.01% |
5,402,608
-628,080
| -10% | -$11.7M |
|
|
XIFR
637
XPLR Infrastructure LP
XIFR
$1.09B
| $102M | 0.01% |
1,982,325
-11,235
| -0.6% | -$544K |
|
638
CRISPR Therapeutics
CRSP
$5.22B
| $101M | 0.01% |
1,375,327
+364,124
| +36% | +$21.3M |
|
639
Sunstone Hotel Investors
SHO
$2.02B
| $100M | 0.01% |
12,325,318
-1,515,155
| -11% | -$13.2M |
|
640
AtriCure
ATRC
$2.21B
| $100M | 0.01% |
2,228,846
+454,992
| +26% | +$19.8M |
|
|
APLS
641
DELISTED
Apellis Pharmaceuticals
APLS
| $98.9M | 0.01% |
3,027,835
+1,776,965
| +142% | +$57.1M |
|
642
Archer Daniels Midland
ADM
$38.6B
| $98.8M | 0.01% |
2,477,042
-207,759
| -8% | -$7.78M |
|
643
Takeda Pharmaceutical
TAK
$55.5B
| $98.5M | 0.01% |
5,495,336
-72,130
| -1% | -$1.29M |
|
644
Generac Holdings
GNRC
$12.8B
| $98.5M | 0.01% |
808,083
+31,113
| +4% | +$3.28M |
|
645
Gold Fields
GFI
$35.4B
| $98.4M | 0.01% |
10,469,422
+2,238,627
| +27% | +$17M |
|
646
Moody's
MCO
$84.6B
| $98.3M | 0.01% |
357,680
-68,371
| -16% | -$17.4M |
|
647
Pennant Group
PNTG
$1.35B
| $97.9M | 0.01% |
4,332,065
-70,940
| -2% | -$1.49M |
|
648
Steven Madden
SHOO
$3.46B
| $96.6M | 0.01% |
3,913,321
+60,519
| +2% | +$1.42M |
|
649
Helen of Troy
HELE
$699M
| $96.3M | 0.01% |
510,840
-4,671
| -0.9% | -$764K |
|
650
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$5.44B
| $95.9M | 0.01% |
3,370,363
+380,438
| +13% | +$10.4M |
|
Similar funds
T. Rowe Price Associates's Q2 2020 Portfolio in Review
As of Q2 2020, T. Rowe Price Associates held 2,591 positions worth $795B, up 26% from $632B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
T. Rowe Price Associates's Q2 2020 filing shows 79 new, 1,096 increased, 1,255 reduced and 100 closed positions. Its largest new stake was Vroom Inc: 200,362 shares worth $797M. The largest sale was Boeing, an estimated $2.05B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2020 buy was Vroom Inc: 200,362 shares worth $797M.
- T. Rowe Price Associates added most to Microsoft in Q2 2020, an estimated $2B increase.
- T. Rowe Price Associates's biggest Q2 2020 reduction was Boeing, cutting an estimated $2.05B.
- T. Rowe Price Associates fully exited Raytheon Company in Q2 2020, selling an estimated $1.01B.
- T. Rowe Price Associates's ten largest holdings make up 25% of its $795B portfolio in Q2 2020.
- T. Rowe Price Associates opened 79 new positions and closed 100 in Q2 2020.
- T. Rowe Price Associates's portfolio value rose 26% quarter-over-quarter to $795B.
Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.